NewsRx

Search our medical news database

Opportunistic Infections

Value of Pneumococcal Vaccine in HIV+ Undetermined

Published in AIDS Weekly, September 4th, 1995

Pneumococcal vaccination was well tolerated and reasonably effective in a group of HIV infected persons entered in a Belgian study, but the cost-effectiveness of routine immunization in this population remains to be determined.

"In Belgium, there is no pneumococcal vaccine commercially available," researcher Marc Vanderbruaene and colleagues wrote ("Equal IgG Antibody Response to Pneumococcal Vaccination in All Stages of HIV Disease," Journal of Infectious Diseases, August 1995;172:551-553).

"Because the efficacy of the 23-valent pneumococcal vaccine among persons with HIV remains unproven, this situation will probably not change in the near...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook